Waleed Shahid @_waleedshahid
During Holtzman's tenure as Biogen's Executive Vice President of Corporate Development, Biogen hiked prices on multiple sclerosis drugs by an average of 16% a year and charged $750,000 for a spinal muscular atrophy drug. https://t.co/onQRsFNeaG — PolitiTweet.org